Cardiometabolic drugs and kidney function - a drug target Mendelian randomisation study

BackgroundChronic kidney disease (CKD) is a growing global public health concern. Using drug target Mendelian randomization (MR) approach, we assessed the effects of cardiometabolic drug classes on kidney function indices in the general population. MethodWe leveraged 93 single nucleotide polymorphisms (SNPs) as genetically proxies for targets of antihypertensives (Ca-channel blockers/CCB, beta-blockers/BB, ACE inhibitors/ACEI), lipid-lowering drugs (PCSK9 inhibitors/PCSK9I, statins, NPC1L1 inhibitors/NPC1L1I), and antidiabetics (metformin, SGLT2 inhibitors/SGLT2I, GLP1R agonist/GLP1RA) drugs. Genetic instruments reflected lowering of systolic blood pressure (SBP), LDL cholesterol, and glycated haemoglobin (HbA1c). We used summary statistics from genome-wide association study (GWAS) of log natural annual change of estimate glomerular filtration rate (eGFR) (n=334,339), cross-sectional creatinine- and cystatin-based eGFR, and blood urea nitrogen (BUN) (n=1,201,909) as kidney function outcome. Two-sample MR and sensitivity methods (simple mode, weighted mode, weighted median, and MR Egger) were applied. ResultsThe annual change of eGFR was attenuated by genetically proxied PCSK9I ({beta}=0.066 per mmol/L LDL lowering; 95%CI 0.008,0.125). Cross-sectional eGFRcrea was increased by CCBs ({beta}=0.006 per 10 mmHg SBP lowering; 95%CI 0.001,0.011), SGLT2I ({beta}=0.024-0.028), MC1 ({beta}=0.022), and GDF15 ({beta}=0.094-0.100) per 6.7 mmol/mol HbA1c lowering. Statins and NPC1L1I may reduce eGFR and SGLT2I may decrease annual eGFR change. ConclusionOur findings provided genetic evidence that specific cardiometabolic drug targets influence kidney function in the general population. These insights may guide personalize drug selection to preserve renal function.